Sen­ti Bio cuts 37% of staff; Evotec pock­ets $25M mile­stone from BMS; No­var­tis buys San­Reno

Plus news about Ory­zon Ge­nomics, Cu­mu­lus On­col­o­gy, Cure­Vac, Ori­on, Glykos Fin­land, Ra­di­ance Bio­phar­ma, Bio­cy­to­gen, Mark­er Ther­a­peu­tics and Hill­e­Vax:

Sen­ti Bio will lay off 37% of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER